Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits

Archives of Pharmacal Research

Volumn 29, Issue 4, 2006, Pages 333-338

  Jun, Shik Choi ^a   Jin, Pil Burm ^b  

^a Chosun University   (South Korea)

^b Chosun Nursing College   (South Korea)

Author keywords

Bioavailability; Cytochrome P 450 3A4; Morin; Nimodipine; P glycoprotein

Indexed keywords

EID: 33646428927     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/bf02968580     Document Type: Article

References (27)

1. Choi, H. J. and Choi, J. S., Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats. Arch. Pharm. Res., 28, 970-976 (2005a).
2. Choi, J. S. and Han, H. K., Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats. Pharmacol. Res., 52, 386-391 (2005b).
3. Dixon, R. A., and Steele, C. L., Flavonoids and isoflavonoids - a gold mine for metabolic engineering. Trends Plant Sci., 4, 394-400 (1999).
4. Epstein, M. and Loutzenhister, R. D., Effects of calcium antagonists on renal hemodynamics, Am. J. Kidney Dis., 16, 10-14 (1990).
5. Fang, S. H., Hou, Y. C., Chang, W. C., Hsiu, S. L., Chao, P. D. L., and Chiang, B. L., Morin sulfates glucuronides exert antiinflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci. 74, 743-756 (2003).
6. Francis, A. R., Shetty, T. K., and Bhattacharya, R. K., Modulating effect of plant flavonoids on the mutagenicity of N-methyl-N-nitro-N-nitrosoguanidine. Carcinogenesis, 10, 1953-1955 (1989).
7. Gan, L. L., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W., and Thakker, D. R., CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos., 24, 344-349 (1996).
8. Gottesman, M. M. and Pastan, I., Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427 (1993).
9. Guengerich, F. P., Brian, W. R., Iwasaki, M., Sari, M. A., Baarnhielm, C., and Berntssom, P., Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrom P-450 3A4, J. Med. Chem., 34, 1834-1844 (1991).
10. Hanasaki, Y., Ogawa, S., and Fukui,S., The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic. Biol. Med. 16, 845-850 (1994).
11. Hodek, P., Trefil, P., and Stiborova, M., Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact., 139, 1-21 (2002).
12. Hsiu, S. L., Hou, Y. C., Wang, Y. H., Tsao, C. W., Su, S. F., and Chao, P. D., Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci., 72, 227-235 (2002).
13. Ito, K., Kusuhara, H., and Sugiyama, Y., Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res., 16, 225-231 (1999).
14. Kazda, S., Garthoff, B., Krause, H. P., and Schlossmann, K., Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments, Arzneimittelforschung., 32, 331-338 (1982).
15. Maruhn, D., Siefert, H. M., Weber, H., Ramsch, K., and Suwelack, D., Pharmacokinetics of nimodipine. communication: absorption, concentration in plasma and excretion after single administration of nimodipine in rat, dog and monkey, Arzneimittelforschung., 35, 1781-1786 (1985).
16. Nguyen, H., Zhang, S., and Morris, M. E., Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J. Pharm. Sci., 92, 250-257 (2003).
17. Qian, M., and Gallo, J. M., High-perfomance liquod chromatographic determinination of the calcium channel blocker nimodipine in monkey plasma, J. Chromatogr., 578, 316-320 (1992).
18. Ramsch, K. D., Ahr, G., Tettenborn, D., and Auer, L. M., Overview on pharmacokinetics of nimodipine in healthy volunteer and in patients with subarachnoid hemorrhage, Neurochirurgia., 28, 74-78 (1985).
19. Rocci, M. L. and Jusko, W. J., LAGRAN program for area and moments in pharmacokinetic analysis, Computer Programs in Biomedicine, 16, 203-209 (1983).
20. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., and Komano, T., P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett., 324, 99-102 (1993).
21. Scherling, D., Buhner, K., Krause, H. P., Karl, W., and Wunsche, C., Biotransformation of nimodipine in rat, dog and monkey, Arzneimittelforschung., 41, 392-398 (1991).
22. Scholz, H., Pharmacological aspects of calcium channel blockers, Cardiovasc. Drugs Ther., 10, 869-872 (1997).
23. 14C] nimodipine in rat, dog and monkey, Arzneimittelforschung., 35, 1787-1794 (1985).
24. Wacher, V. H., Silverman, J. A., Zhang, Y., and Benet, L Z., Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 87, 1322-1330 (1998).
25. Wacher, V. J., Salphati, L., and Benet, L. Z., Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev., 46, 89-102 (2001).
26. Watkins, P. B., The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev., 27, 161-170 (1996).
27. Zhang, S. and Morris, M. E., Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther., 304, 1258-1267 (2003).